PT1082962E - Utilizacao de derivados do acido 2-hidroxi-4-trifluorometilbenzoico como inibidores da activacao dos factores de transcricao nucleares nf-(k)b - Google Patents

Utilizacao de derivados do acido 2-hidroxi-4-trifluorometilbenzoico como inibidores da activacao dos factores de transcricao nucleares nf-(k)b

Info

Publication number
PT1082962E
PT1082962E PT99920872T PT99920872T PT1082962E PT 1082962 E PT1082962 E PT 1082962E PT 99920872 T PT99920872 T PT 99920872T PT 99920872 T PT99920872 T PT 99920872T PT 1082962 E PT1082962 E PT 1082962E
Authority
PT
Portugal
Prior art keywords
hydroxy
acid derivatives
trifluoromethylbenzoic acid
nuclear transcription
transcription factors
Prior art date
Application number
PT99920872T
Other languages
English (en)
Portuguese (pt)
Inventor
Manuel Merlos Roca
Alberto Fernandez De Arriba
Fernando Cavalcanti De Maria
Agusti Miralles Acosta
Mariano Sanchez Crespo
Julian Garcia Rafanell
Javier Forn Dalmau
Original Assignee
Uriach & Cia Sa J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uriach & Cia Sa J filed Critical Uriach & Cia Sa J
Publication of PT1082962E publication Critical patent/PT1082962E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT99920872T 1998-05-27 1999-05-26 Utilizacao de derivados do acido 2-hidroxi-4-trifluorometilbenzoico como inibidores da activacao dos factores de transcricao nucleares nf-(k)b PT1082962E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801154A ES2136581B1 (es) 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.

Publications (1)

Publication Number Publication Date
PT1082962E true PT1082962E (pt) 2003-11-28

Family

ID=8304002

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99920872T PT1082962E (pt) 1998-05-27 1999-05-26 Utilizacao de derivados do acido 2-hidroxi-4-trifluorometilbenzoico como inibidores da activacao dos factores de transcricao nucleares nf-(k)b

Country Status (14)

Country Link
US (2) US6414025B1 (https=)
EP (2) EP1082962B1 (https=)
JP (1) JP2002516283A (https=)
KR (2) KR100762156B1 (https=)
AT (1) ATE245987T1 (https=)
AU (1) AU3828699A (https=)
BR (1) BR9911598A (https=)
CA (1) CA2332863A1 (https=)
DE (1) DE69910019T2 (https=)
DK (1) DK1082962T3 (https=)
ES (2) ES2136581B1 (https=)
NO (1) NO20005981L (https=)
PT (1) PT1082962E (https=)
WO (1) WO1999061030A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2154242B1 (es) * 1999-09-03 2001-10-16 Uriach & Cia Sa J Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb.
US20040101488A1 (en) * 2000-03-24 2004-05-27 Balaram Ghosh Method for the prevention of septic shock lethality using curcumin
ES2190373B1 (es) * 2001-12-07 2004-10-16 J. URIACH & CIA, S.A. Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
CA2497977A1 (en) 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
JP5780521B2 (ja) 2008-05-28 2015-09-16 リベラジェン・バイオファーマ・インコーポレイテッドＲｅｖｅｒａＧｅｎ ＢｉｏＰｈａｒｍａ，Ｉｎｃ． 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子
NZ755378A (en) 2009-03-18 2022-07-29 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
CN103665012B (zh) * 2013-12-06 2016-06-22 辽宁师范大学 新型三氟柳无机药物化合物及合成方法
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
US20180016314A1 (en) * 2016-07-12 2018-01-18 Children's Hospital Medical Center Treatment of disease via transcription factor modulation
JP6923659B2 (ja) * 2016-10-14 2021-08-25 アンスティテュ パスツール デ モンテビデオＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ Ｄｅ Ｍｏｎｔｅｖｉｄｅｏ 多能性抗炎症及び代謝調節剤を用いた炎症関連症状の治療方法
KR101975603B1 (ko) 2018-09-14 2019-08-28 이영문 조력 발전장치
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096252A (en) * 1976-06-10 1978-06-20 J. Uriach & Cia S.A. 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents
IT1276071B1 (it) * 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria

Also Published As

Publication number Publication date
DE69910019D1 (de) 2003-09-04
NO20005981D0 (no) 2000-11-27
JP2002516283A (ja) 2002-06-04
EP1362592A1 (en) 2003-11-19
ATE245987T1 (de) 2003-08-15
CA2332863A1 (en) 1999-12-02
WO1999061030A1 (es) 1999-12-02
EP1082962B1 (en) 2003-07-30
US20030032630A1 (en) 2003-02-13
US6610745B2 (en) 2003-08-26
DK1082962T3 (da) 2003-11-24
NO20005981L (no) 2000-12-12
KR20010052404A (ko) 2001-06-25
ES2204129T3 (es) 2004-04-16
BR9911598A (pt) 2001-02-13
KR20070006943A (ko) 2007-01-11
KR100762156B1 (ko) 2007-10-04
EP1082962A1 (en) 2001-03-14
ES2136581A1 (es) 1999-11-16
DE69910019T2 (de) 2004-05-06
ES2136581B1 (es) 2000-09-16
AU3828699A (en) 1999-12-13
KR100713601B1 (ko) 2007-05-02
US6414025B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
PT1082962E (pt) Utilizacao de derivados do acido 2-hidroxi-4-trifluorometilbenzoico como inibidores da activacao dos factores de transcricao nucleares nf-(k)b
NO991685D0 (no) Anvendelse av 1-benzyl-3-(substituert hetaryl)-kondenserte pyrazolderivater for behandling av spesielle sykdommer i hjerte-kretsl°psystemet og sentralnervesystemet
ES2155601T3 (es) Compuestos de benzolactama sustituidos como antagonistas de la sustancia p.
MX9603479A (es) Derivados de 4-amino de acido micofenolico con actividad inmunosupresora.
EP1140840A4 (en) -G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREASINE AS RAF KINASE INHIBITORS
BR0009814A (pt) Processo para tratar de uma doença associada com o receptor-beta estrogênico
ATE552891T1 (de) Kombination von sauren-proteaseenzymen und sauren pufferlösungen sowie deren verwendung
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
BR9908869A (pt) Composição para evitar ou tratar distúrbios da pele
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
PT801564E (pt) Utilizacao de nebivolol como agente anti-aterogernico
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
TR199903053T2 (xx) Benzimidazol t�revleri.
BR9811006A (pt) Sequência de dna, cassete de expressão, uso do mesmo, processo para transformar uma planta, planta com um elevado teor em vitamina e, processo para gerar plantas com um elevado teor em vitamina e e para gerar plantas com elevada resistência a inibidores de hppd, sistema de teste, subtância herbicamente ativa, uso de uma planta, e, planta com elevada resistência a inibidores de hppd
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
ATE406382T1 (de) Tropoelastinderivate
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
EP1157698A3 (en) Treatment of inflammatory diseases with oxypurine nucleosides
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
EP0974363A4 (en) REMEDIES FOR ADDICTION
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
ATE419346T1 (de) Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ES2124861T3 (es) Derivados de aminoacidos y su utilizacion como inhibidores de la encefalinasa.